Last reviewed · How we verify
NCT06922240: RED-HEART
Riociguat-Discontinue Effects on Right HEART in CTEPH (RED-HEART)
Phase 3 trial testing Riociguat in Chronic Thromboembolic Pulmonary Hypertension in 68 participants. Currently enrolling.
30 October 2026
Quick facts
| Lead sponsor | Suqiao Yang |
|---|---|
| Phase | Phase 3 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 68 |
| Start date | 21 March 2025 |
| Primary completion | 30 October 2026 |
| Estimated completion | 31 October 2027 |
| Sites | 3 locations across China |
Drugs / interventions tested
- Riociguat (RIOCIGUAT) — full drug profile →
- Routine Treatment — full drug profile →
Conditions studied
- Chronic Thromboembolic Pulmonary Hypertension — all drugs for Chronic Thromboembolic Pulmonary Hypertension →
Sponsor
Suqiao Yang
Who can join
18 and older, any sex, with Chronic Thromboembolic Pulmonary Hypertension. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Riociguat and balloon pulmonary angioplasty (BPA) are established standard-of-care interventions for inoperable chronic thromboembolic pulmonary hypertension (CTEPH) with comparable evidence levels. However, the optimal combined treatment strategy remains unclear. Specifically, there is no consensus on whether riociguat should be continued long-term after achieving hemodynamic stability with BPA. Additionally, the long-term effects of riociguat discontinuation on right ventricular (RV) structure and function remain poorly characterized, particularly due to the lack of comprehensive noninvasive evaluations integrating cardiac magnetic resonance (CMR) and echocardiography. This prospective study aims to determine the hemodynamic impact of riociguat discontinuation in inoperable CTEPH patients who have achieved BPA treatment endpoints using right heart catheterization (RHC). Evaluate RV remodeling and functional changes after riociguat cessation through multimodal noninvasive imaging (CMR, echocardiography). Assess safety outcomes and identify potential rebound pulmonary hypertension or decompensated RV dysfunction associated with riociguat withdrawal.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06922240
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Riociguat
Trials testing the same drug.
- NCT05140525 — Effects of Combination Medical Therapy Followed by BPA on Right Ventricular-PA Coupling and Hemodynamics in CTEPH · Phase 3 · recruiting
- NCT05582811 — Effect of Riocigaut on Cerebral Vasodilation and Headache Induction in Healthy Volunteers · NA · completed
- NCT05762146 — Networked Drug REpurposing for Mechanism-based neuroPrOtection in Acute Ischaemic STROKE · Phase 2 · unknown
- NCT04954742 — Effects of Riociguat on RIght VEntricular Size and Function in PAH and CTEPH · Phase 4 · terminated
- NCT04211272 — A 2-part Study to Investigate the Effect of Macitentan in Healthy Male Participants · Phase 1 · completed
Other recruiting trials for Chronic Thromboembolic Pulmonary Hypertension
Currently open trials in the same condition.
- NCT07272798 — Cardiac Self-Efficacy in Patients With Chronic Thromboembolic Pulmonary Hypertension · recruiting
- NCT07254078 — Registry of Patients With chrOnic thromboemboLic Pulmonary hypErTension · recruiting
- NCT06081881 — Chronic Thromboembolic Pulmonary Hypertension After Pulmonary Embolism · recruiting
- NCT06715280 — Switching of Sildenafil to Riociguat in CTEPH Patients · Phase 4 · recruiting
- NCT05110066 — BPA vs. PEA in CTEPH · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06922240 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Suqiao Yang
- Last refreshed: 30 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06922240.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing